| 493 | Humans |
| 239 | Animals |
| 224 | Female |
| 212 | Male |
| 140 | Chloroquine (pharmacology) |
| 120 | Mice |
| 99 | Chloroquine (therapeutic use) |
| 99 | Cell Line, Tumor |
| 96 | Autophagy (drug effects) |
| 95 | Adult |
| 84 | Middle Aged |
| 74 | Lung Neoplasms (pathology) |
| 70 | Lung Neoplasms (drug therapy) |
| 64 | Chloroquine |
| 61 | Hydroxychloroquine (therapeutic use) |
| 59 | Rheumatoid arthritis |
| 58 | Rats |
| 58 | Child |
| 54 | Lung (metabolism) |
| 54 | Apoptosis (drug effects) |
| 52 | Aged |
| 50 | Lung Neoplasms (metabolism) |
| 49 | Treatment Outcome |
| 47 | Cells, Cultured |
| 44 | Cell Proliferation (drug effects) |
| 42 | Lung |
| 42 | Lung (pathology) |
| 42 | Lung (drug effects) |
| 42 | Cell Line |
| 41 | Antineoplastic Agents (pharmacology) |
| 39 | Treatment |
| 39 | Cell Survival (drug effects) |
| 38 | Lung Diseases (drug therapy) |
| 38 | Human |
| 37 | Carcinoma, Non-Small-Cell Lung (pathology) |
| 36 | Sarcoidosis |
| 36 | Sarcoidosis (drug therapy) |
| 36 | Autophagy |
| 33 | Plasmodium falciparum |
| 33 | Mice, Inbred BALB C |
| 33 | Infant |
| 33 | Adolescent |
| 32 | Dose-Response Relationship, Drug |
| 32 | Carcinoma, Non-Small-Cell Lung (drug therapy) |
| 31 | Lung Diseases, Interstitial (drug therapy) |
| 30 | Signal Transduction (drug effects) |
| 29 | Systemic lupus erythematosus |
| 29 | Malaria |
| 29 | Antimalarial |
| 28 | Time Factors |
| 28 | Retrospective Studies |
| 28 | Drug Therapy, Combination |
| 28 | Antimalarials (pharmacology) |
| 27 | Mice, Nude |
| 27 | Immunosuppressive Agents (therapeutic use) |
| 27 | A549 Cells |
| 26 | Xenograft Model Antitumor Assays |
| 26 | Tomography, X-Ray Computed |
| 26 | Lung Neoplasms (genetics) |
| 26 | Disease Models, Animal |
| 26 | Child, Preschool |
| 25 | In vitro |
| 25 | Apoptosis |
| 24 | Prognosis |
| 24 | Microtubule-Associated Proteins (metabolism) |
| 24 | Drug Synergism |
| 24 | Antirheumatic Agents (therapeutic use) |
| 23 | Hydroxychloroquine |
| 23 | Diagnosis, Differential |
| 22 | Radiography |
| 22 | Mutation |
| 21 | Plasmodium falciparum (drug effects) |
| 21 | Mice, Inbred C57BL |
| 21 | Methotrexate |
| 21 | Follow-Up Studies |
| 21 | Chloroquine (administration & dosage) |
| 21 | Biopsy |
| 21 | Adrenal Cortex Hormones (therapeutic use) |
| 20 | Parasiticide |
| 20 | Glucocorticoids (therapeutic use) |
| 20 | Chemotherapy |
| 20 | Case study |
| 20 | Antineoplastic Agents (therapeutic use) |
| 19 | chloroquine |
| 19 | Tumor Cells, Cultured |
| 19 | Lysosomes (metabolism) |
| 19 | Carcinoma, Non-Small-Cell Lung (metabolism) |
| 18 | TOR Serine-Threonine Kinases (metabolism) |
| 18 | Signal Transduction |
| 18 | Lung Diseases (diagnosis) |
| 18 | Hydrogen-Ion Concentration |
| 17 | Reactive Oxygen Species (metabolism) |
| 17 | Proto-Oncogene Proteins c-akt (metabolism) |
| 17 | Lung (cytology) |
| 17 | Liver (metabolism) |
| 17 | Cytotoxicity |
| 17 | Cyclophosphamide (therapeutic use) |
| 16 | Toxicity |
| 16 | Methotrexate (therapeutic use) |
| 16 | Lupus Erythematosus, Systemic (complications) |
| 16 | Lung Diseases, Interstitial (diagnosis) |
| 16 | Infant, Newborn |
| 16 | Chloroquine (adverse effects) |
| 15 | Protein Kinase Inhibitors (pharmacology) |
| 15 | Prednisone (therapeutic use) |
| 15 | Prednisolone (therapeutic use) |
| 15 | Lung Diseases, Interstitial (etiology) |
| 15 | Hydroxychloroquine (administration & dosage) |
| 15 | Dermatomyositis |
| 15 | Chloroquine (metabolism) |
| 15 | Carcinoma, Non-Small-Cell Lung (genetics) |
| 14 | rheumatoid arthritis |
| 14 | Respiratory Function Tests |
| 14 | Rat |
| 14 | Molecular Structure |
| 14 | Microtubule-Associated Proteins (genetics) |
| 14 | Lung (diagnostic imaging) |
| 14 | In Vitro Techniques |
| 14 | Hemosiderosis (drug therapy) |
| 14 | Drug Resistance, Neoplasm (drug effects) |
| 14 | Azathioprine (therapeutic use) |
| 13 | Receptors, G-Protein-Coupled (metabolism) |
| 13 | Rats, Sprague-Dawley |
| 13 | Pregnancy |
| 13 | Malaria (drug therapy) |
| 13 | Lysosomes (drug effects) |
| 13 | Lupus Erythematosus, Systemic (drug therapy) |
| 13 | Lung Diseases, Interstitial (therapy) |
| 13 | Lung Diseases, Interstitial (genetics) |
| 13 | Kidney (metabolism) |
| 13 | ErbB Receptors (genetics) |
| 13 | Blotting, Western |
| 13 | Autophagy (physiology) |
| 13 | Animal |
| 12 | Structure-Activity Relationship |
| 12 | SLE |
| 12 | Phosphorylation (drug effects) |
| 12 | Kinetics |
| 12 | Gene Expression Regulation, Neoplastic (drug effects) |
| 12 | Fibroblasts (drug effects) |
| 12 | Chronic Disease |
| 12 | Arthritis, Rheumatoid (drug therapy) |
| 12 | Antimalarials (therapeutic use) |
| 12 | Anti-Inflammatory Agents (therapeutic use) |
| 11 | Tissue Distribution |
| 11 | RNA, Messenger (metabolism) |
| 11 | Plant Extracts (pharmacology) |
| 11 | Phospholipids (metabolism) |
| 11 | Hydroxychloroquine (adverse effects) |
| 11 | Chloroquine (chemistry) |
| 11 | Antineoplastic agent |
| 11 | Antineoplastic Agents, Phytogenic (pharmacology) |
| 11 | Antimalarials (chemistry) |
| 10 | Therapy |
| 10 | Sarcoidosis (diagnosis) |
| 10 | Rheumatoid Arthritis |
| 10 | Receptors, G-Protein-Coupled (agonists) |
| 10 | Pulmonary Fibrosis (drug therapy) |
| 10 | Polymyositis |
| 10 | Myocardium (metabolism) |
| 10 | Methylprednisolone (therapeutic use) |
| 10 | Lung Diseases (etiology) |
| 10 | Hydroxychloroquine (pharmacology) |
| 10 | Guinea Pigs |
| 10 | Fibroblasts (metabolism) |
| 10 | ErbB Receptors (antagonists & inhibitors) |
| 10 | Diagnosis |
| 10 | Autophagy (genetics) |
| 10 | Antineoplastic Agents (chemistry) |
| 10 | Antineoplastic Agents (administration & dosage) |
| 10 | Adenine (analogs & derivatives) |
| 9 | systemic lupus erythematosus |
| 9 | malaria |
| 9 | Young Adult |
| 9 | Transfection |
| 9 | Spleen (metabolism) |
| 9 | Sjogren's Syndrome (complications) |
| 9 | Rabbits |
| 9 | RNA Interference |
| 9 | Pulmonary Surfactant-Associated Protein C (genetics) |
| 9 | Muscle, Smooth (drug effects) |
| 9 | Lung Diseases, Interstitial (physiopathology) |
| 9 | Lung Diseases, Interstitial (complications) |
| 9 | Lung Diseases (pathology) |
| 9 | Interstitial pneumonitis |
| 9 | Idiopathic |
| 9 | Drug Resistance |
| 9 | Cell Cycle (drug effects) |
| 9 | Brain (metabolism) |
| 9 | Arthritis |
| 9 | Antirheumatic agent |
| 9 | Adenocarcinoma (drug therapy) |
| 9 | Adenine (pharmacology) |
| 8 | Vasculitis |
| 8 | Tumor cell |
| 8 | TOR Serine-Threonine Kinases (antagonists & inhibitors) |
| 8 | Syndrome |
| 8 | Sarcoidosis, Pulmonary (drug therapy) |
| 8 | Rituximab |
| 8 | Respiratory system |
| 8 | Rats, Inbred Strains |
| 8 | Radiography, Thoracic |
| 8 | Quinazolines (pharmacology) |
| 8 | Plasmodium (drug effects) |
| 8 | Phosphorylation |
| 8 | Neoplasm Metastasis |
| 8 | Mitochondria (drug effects) |
| 8 | Microscopy, Electron, Transmission |
| 8 | Membrane Potential, Mitochondrial (drug effects) |
| 8 | Lupus |
| 8 | Lupus erythematosus |
| 8 | Lung Neoplasms (secondary) |
| 8 | Lung Diseases, Interstitial (pathology) |
| 8 | Lung Diseases (complications) |
| 8 | Lung (physiology) |
| 8 | Infliximab |
| 8 | Immunosuppressive Agents (adverse effects) |
| 8 | Hemosiderosis (diagnosis) |
| 8 | Gene Knockdown Techniques |
| 8 | Fatal Outcome |
| 8 | ErbB Receptors (metabolism) |
| 8 | Epithelial Cells (metabolism) |
| 8 | Drug Screening Assays, Antitumor |
| 8 | Disease Progression |
| 8 | Cisplatin (pharmacology) |
| 8 | Cell Survival |
| 8 | Cell Movement (drug effects) |
| 8 | Caspase 3 (metabolism) |
| 8 | Biological activity |
| 8 | Arthritis, Rheumatoid (complications) |
| 8 | Antiphospholipid syndrome |
| 8 | Antimalarials |
| 8 | Anti-Bacterial Agents (therapeutic use) |
| 8 | Amebiasis |
| 7 | sarcoidosis |
| 7 | Virus Replication (drug effects) |
| 7 | Tumor Burden (drug effects) |
| 7 | Systemic sclerosis |
| 7 | Skin |
| 7 | Sjogren's Syndrome (drug therapy) |
| 7 | Scleroderma |
| 7 | SLE, systemic lupus erythematosus |
| 7 | RNA, Messenger (genetics) |
| 7 | Pulmonary Fibrosis (pathology) |
| 7 | Phosphatidylinositol 3-Kinases (metabolism) |
| 7 | Phagosomes (metabolism) |
| 7 | Neoplasm Transplantation |
| 7 | Myocytes, Smooth Muscle (metabolism) |
| 7 | Myocytes, Smooth Muscle (drug effects) |
| 7 | Mitochondria (metabolism) |
| 7 | Microscopy, Electron |
| 7 | Mechanism of action |
| 7 | Macrophage |
| 7 | Lung Neoplasms (immunology) |
| 7 | Lung Diseases |
| 7 | Lung Diseases, Parasitic |
| 7 | Lung (analysis) |
| 7 | Inhibitory Concentration 50 |
| 7 | Inflammation |
| 7 | Infection |
| 7 | Incidence |
| 7 | Immunosuppressive agent |
| 7 | Hemosiderosis |
| 7 | Hemorrhage (etiology) |
| 7 | Gene Expression Regulation, Neoplastic |
| 7 | Gefitinib |
| 7 | Flow Cytometry |
| 7 | Enzyme Inhibitors (pharmacology) |
| 7 | Endocytosis |
| 7 | Emetine (therapeutic use) |
| 7 | Drug Resistance, Neoplasm |
| 7 | Drug Resistance, Neoplasm (genetics) |
| 7 | Corticosteroid |
| 7 | Chronic |
| 7 | Chloroquine (toxicity) |
| 7 | Chloroquine (analogs & derivatives) |
| 7 | Cell line |
| 7 | Case-Control Studies |
| 7 | Breast cancer |
| 7 | Beclin-1 (metabolism) |
| 7 | Asthma (drug therapy) |
| 7 | Apoptosis Regulatory Proteins (metabolism) |
| 7 | Antineoplastic Combined Chemotherapy Protocols (pharmacology) |
| 7 | Aged, 80 and over |
| 7 | Acute Disease |
| 6 | multidrug resistance |
| 6 | hydroxychloroquine |
| 6 | gene therapy |
| 6 | autophagy |
| 6 | Tumor Suppressor Protein p53 (metabolism) |
| 6 | Taste |
| 6 | Severity of Illness Index |
| 6 | Sarcoidosis (pathology) |
| 6 | Risk Factors |
| 6 | Resistance |
| 6 | Recurrence |
| 6 | Rats, Wistar |
| 6 | Radionuclide Imaging |
| 6 | Pulmonary hypertension |
| 6 | Proto-Oncogene Proteins c-akt (antagonists & inhibitors) |
| 6 | Protein Binding |
| 6 | Prevalence |
| 6 | Plant origin |
| 6 | Phenotype |
| 6 | Pharmacology |
| 6 | Pediatrics |
| 6 | Muscles (metabolism) |
| 6 | Muscle Relaxation (drug effects) |
| 6 | Microscopy, Fluorescence |
| 6 | Membrane Proteins (metabolism) |
| 6 | Mammalia |
| 6 | Macrophages (drug effects) |
| 6 | Macrolides (pharmacology) |
| 6 | Lysosomes |
| 6 | Lupus Erythematosus, Systemic (diagnosis) |
| 6 | Lung Neoplasms |
| 6 | Lung Neoplasms (therapy) |
| 6 | Lung Diseases, Interstitial (diagnostic imaging) |
| 6 | Lung Diseases (therapy) |
| 6 | Lung (physiopathology) |
| 6 | Lung (embryology) |
| 6 | Liver |
| 6 | Lipidoses (chemically induced) |
| 6 | Leflunomide |
| 6 | Indoles (pharmacology) |
| 6 | Immunosuppressive Agents (administration & dosage) |
| 6 | Immunohistochemistry |
| 6 | Hypoxia |
| 6 | HeLa Cells |
| 6 | HCT116 Cells |
| 6 | Gene Transfer Techniques |
| 6 | Gene Expression Regulation (drug effects) |
| 6 | Fibrosis |
| 6 | Exploration |
| 6 | Etanercept |
| 6 | Established cell line |
| 6 | Epithelial Cells (drug effects) |
| 6 | Enzyme inhibitor |
| 6 | Dysentery, Amebic |
| 6 | Drug resistance |
| 6 | Drug Evaluation, Preclinical |
| 6 | Drug Administration Schedule |
| 6 | Dogs |
| 6 | Dermatomyositis (drug therapy) |
| 6 | DNA |
| 6 | Cyclophosphamide |
| 6 | Clinical Trials as Topic |
| 6 | Chlorphentermine |
| 6 | Chloroquine (pharmacokinetics) |
| 6 | Chloroquine (blood) |
| 6 | Cancer |
| 6 | Bronchodilator Agents (pharmacology) |
| 6 | Beclin-1 (genetics) |
| 6 | Asthma |
| 6 | Apoptosis (genetics) |
| 6 | Antiviral Agents (pharmacology) |
| 6 | Antirheumatic Agents (adverse effects) |
| 6 | Antimalarials (isolation & purification) |
| 6 | Antimalarials (chemical synthesis) |
| 6 | Antimalarials (adverse effects) |
| 6 | Anti-Inflammatory Agents (administration & dosage) |
| 6 | Age Factors |
| 6 | Adenocarcinoma of Lung |
| 6 | Adenocarcinoma (pathology) |
| 6 | Adaptor Proteins, Signal Transducing (metabolism) |
| 6 | AMP-Activated Protein Kinases (metabolism) |
| 5 | transfection |
| 5 | cytotoxicity |
| 5 | Treatment efficiency |
| 5 | Survival Analysis |
| 5 | Sjögren's syndrome |
| 5 | Sirolimus (pharmacology) |
| 5 | Sex Factors |
| 5 | Rituximab (therapeutic use) |
| 5 | Reverse Transcriptase Polymerase Chain Reaction |
| 5 | Respiratory tract |
| 5 | Respiratory disease |
| 5 | Respiratory Distress Syndrome, Newborn (genetics) |
| 5 | Respiration, Artificial |
| 5 | RNA, Small Interfering (genetics) |
| 5 | RA, rheumatoid arthritis |
| 5 | Quinolines (pharmacology) |
| 5 | Quinine (therapeutic use) |
| 5 | Q fever |
| 5 | Pyridines (pharmacology) |
| 5 | Pulmonary Fibrosis (diagnosis) |
| 5 | Prednisolone |
| 5 | Prednisolone (administration & dosage) |
| 5 | Plasmodium |
| 5 | Plasmodium vivax |
| 5 | Plants, Medicinal (chemistry) |
| 5 | Plant Extracts (chemistry) |
| 5 | Pigments |
| 5 | Pharmacognosy |
| 5 | Phagosomes (drug effects) |
| 5 | Penicillamine (therapeutic use) |
| 5 | PBS |
| 5 | Oxygen Inhalation Therapy |
| 5 | Organ Size |
| 5 | Neoplasms (pathology) |
| 5 | Neoplasms (drug therapy) |
| 5 | NF-kappa B (metabolism) |
| 5 | Mycophenolic Acid (therapeutic use) |
| 5 | Muscle, Smooth (physiology) |
| 5 | Muscle Relaxation (physiology) |
| 5 | Mouse |
| 5 | Models, Biological |
| 5 | Mice, Knockout |
| 5 | Metronidazole (therapeutic use) |
| 5 | Methylene blue |
| 5 | Mefloquine |
| 5 | Medicinal plant |
| 5 | Malignancy |
| 5 | MAP Kinase Signaling System (drug effects) |
| 5 | Lysosomes (enzymology) |
| 5 | Lung function |
| 5 | Lung disease |
| 5 | Lung Diseases, Parasitic (drug therapy) |
| 5 | Lung (ultrastructure) |
| 5 | Lung (microbiology) |
| 5 | Lung (immunology) |
| 5 | Lung (enzymology) |
| 5 | Lung (chemistry) |
| 5 | Liver Abscess |
| 5 | Liver Abscess, Amebic |
| 5 | Liver Abscess, Amebic (complications) |
| 5 | Liver (drug effects) |
| 5 | Iron |
| 5 | Interstitial lung disease |
| 5 | Inflammation (pathology) |
| 5 | India |
| 5 | Hydroxychloroquine (metabolism) |
| 5 | HEK293 Cells |
| 5 | Fetus |
| 5 | Epithelial cell |
| 5 | Enzyme-Linked Immunosorbent Assay |
| 5 | Enzyme Inhibitors (therapeutic use) |
| 5 | Endothelium, Vascular (metabolism) |
| 5 | Emetine |
| 5 | Edema |
| 5 | Dyspnea (etiology) |
| 5 | Drug |
| 5 | Drug interaction |
| 5 | Drug Interactions |
| 5 | Drug Combinations |
| 5 | Down-Regulation (drug effects) |
| 5 | Dermatomyositis (diagnosis) |
| 5 | DNA (chemistry) |
| 5 | DMARD, disease modifying antirheumatic drug |
| 5 | Cystic fibrosis |
| 5 | Cyclophosphamide (administration & dosage) |
| 5 | Corticosteroids |
| 5 | Complication |
| 5 | Chloroquine (analysis) |
| 5 | Children |
| 5 | Cell culture |
| 5 | Cell Proliferation |
| 5 | Bronchoalveolar Lavage |
| 5 | Body Weight |
| 5 | Biological receptor |
| 5 | Binding Sites |
| 5 | Beclin-1 |
| 5 | Azathioprine |
| 5 | Atherosclerosis |
| 5 | Artemisinin |
| 5 | Anti-TNF |
| 5 | Anti-Bacterial Agents (pharmacology) |
| 5 | Administration, Inhalation |
| 5 | Adenocarcinoma (metabolism) |
| 5 | Adalimumab |
| 4 | polymyositis |
| 4 | phospholipidosis |
| 4 | ferroquine |
| 4 | drug resistance |
| 4 | autoantibodies |
| 4 | arthritis |
| 4 | amiodarone |
| 4 | Tumor Necrosis Factor-alpha (antagonists & inhibitors) |
| 4 | Tropical medicine |
| 4 | Toxicology |
| 4 | Tomography, X-Ray Computed (methods) |
| 4 | Toll-Like Receptor 9 (metabolism) |
| 4 | Tandem Mass Spectrometry (methods) |
| 4 | TNF, tumour necrosis factor |
| 4 | Systemic Lupus Erythematosus |
| 4 | Swine |
| 4 | Survival Rate |
| 4 | Surfactant |
| 4 | Spleen |
| 4 | Sirolimus (therapeutic use) |
| 4 | Signal Transduction (physiology) |
| 4 | Scleroderma, Systemic (complications) |
| 4 | Sarcoidosis (physiopathology) |
| 4 | Sarcoidosis (diagnostic imaging) |
| 4 | Sarcoidosis (complications) |
| 4 | STAT3 Transcription Factor (metabolism) |
| 4 | Risk Assessment |
| 4 | Respiratory System (metabolism) |
| 4 | Respiratory Distress Syndrome, Newborn (etiology) |
| 4 | Randomized Controlled Trials as Topic |
